ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer

SAN DIEGO—(BUSINESS WIRE)—Apr. 1, 2019—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system (CNS)disorders, today announced the promotion of Elena Ridloff, CFA toExecutive Vice President, Chief Financial Officer. Ms. Ridloff joinedACADIA Pharmaceuticals in April 2018 as Senior Vice President, InvestorRelations and has served as the company’s Interim Chief FinancialOfficer since October 2018.

This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20190401005246/en/

Elena Ridloff, CFA, Executive Vice President, Chief Financial Officer (Photo: Business Wire)

“I am really delighted to make this announcement. Elena has contributedto significant achievements for our business since joining ACADIA lastyear. She has played a pivotal role in our executive management teamleading our financial operations while strengthening our shareholderbase and elevating our corporate and financial communications,” saidSteve Davis, ACADIA’s Chief Executive Officer. “Elena has quickly provedto be a valuable member, bringing new and different expertise to theteam. I look forward to continuing to work with her at this importantand exciting time in our company’s history.”

“I am honored to take on this new role with ACADIA’s experiencedleadership team and help lead us through our next phase of financialgrowth,” said Ms. Ridloff. “We are well positioned to continue to growNUPLAZID in Parkinson’s disease psychosis, leverage pimavanserin inadditional indications, and expand our pipeline through disciplinedbusiness development.”

Previously Ms. Ridloff was Senior Vice President, Investor Relations andInterim Chief Financial Officer at ACADIA Pharmaceuticals. Prior tojoining ACADIA, she was Vice President, Investor Relations at AlexionPharmaceuticals and served as a member of the Operating Committee.Additionally, Ms. Ridloff was Chief Executive Officer and ManagingMember of BIOVISIO, an independent consulting firm providing strategic,financial and investor relations counsel to the life sciences industry.She was also a Managing Director at Maverick Capital, a hedge fund basedin New York, and was responsible for investments in the biotechnology,pharmaceutical, medical device and life science sectors. Ms. Ridloffearned her B.A. in History and Sociology of Science from the Universityof Pennsylvania. She is also a CFA^® charterholder.

About NUPLAZID^® (pimavanserin)
NUPLAZIDis the first and only FDA-approved treatment for hallucinations anddelusions associated with Parkinson’s disease psychosis. NUPLAZID is anon-dopaminergic, selective serotonin inverse agonist (SSIA)preferentially targeting 5-HT_2A receptors that are thought toplay an important role in Parkinson’s disease psychosis. NUPLAZID is anoral medicine taken once a day with a recommended dose of 34 mg. ACADIAdiscovered and developed this new chemical entity and holds worldwiderights to develop and commercialize NUPLAZID.

About ACADIA Pharmaceuticals
ACADIA is a biopharmaceuticalcompany focused on the development and commercialization of innovativemedicines to address unmet medical needs in central nervous systemdisorders. ACADIA has developed and is commercializing the first andonly medicine approved for the treatment of hallucinations and delusionsassociated with Parkinson’s disease psychosis. In addition, ACADIA hasongoing clinical development efforts in additional areas withsignificant unmet need, including dementia-related psychosis,schizophrenia inadequate response, schizophrenia-negative symptoms,major depressive disorder, and Rett syndrome. This press release andfurther information about ACADIA can be found at: www.acadia-pharm.com.

Forward-Looking Statements
Statements in this press releasethat are not strictly historical in nature are forward-lookingstatements. These statements include, but are not limited to, statementsrelated to the potential opportunity for future growth in sales ofNUPLAZID. These statements are only predictions based on currentinformation and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingthe uncertainty of future commercial sales and related items that wouldimpact net sales during 2019, the risks and uncertainties inherent indrug discovery, development, approval and commercialization, and thefact that past results of clinical trials may not be indicative offuture trial results. For a discussion of these and other factors,please refer to ACADIA’s annual report on Form 10-K for the year endedDecember 31, 2018 as well as ACADIA’s subsequent filings with theSecurities and Exchange Commission. You are cautioned not to place unduereliance on these forward-looking statements, which speak only as of thedate hereof. This caution is made under the safe harbor provisions ofthe Private Securities Litigation Reform Act of 1995. Allforward-looking statements are qualified in their entirety by thiscautionary statement and ACADIA undertakes no obligation to revise orupdate this press release to reflect events or circumstances after thedate hereof, except as required by law.

Important Safety Information and Indication forNUPLAZID (pimavanserin)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITHDEMENTIA-RELATED PSYCHOSIS

• Elderly patients with dementia-related psychosis treated withantipsychotic drugs are at an increased risk of death.
• NUPLAZID is not approved for the treatment of patients withdementia-related psychosis unrelated to the hallucinations anddelusions associated with Parkinson’s disease psychosis.

Contraindication: NUPLAZID is contraindicated in patients with ahistory of a hypersensitivity reaction to pimavanserin or any of itscomponents. Rash, urticaria, and reactions consistent with angioedema(e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea)have been reported.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. Theuse of NUPLAZID should be avoided in patients with known QT prolongationor in combination with other drugs known to prolong QT intervalincluding Class 1A antiarrhythmics or Class 3 antiarrhythmics, certainantipsychotic medications, and certain antibiotics. NUPLAZID should alsobe avoided in patients with a history of cardiac arrhythmias, as well asother circumstances that may increase the risk of the occurrence oftorsade de pointes and/or sudden death, including symptomaticbradycardia, hypokalemia or hypomagnesemia, and presence of congenitalprolongation of the QT interval.

Adverse Reactions: The most common adverse reactions (≥2% forNUPLAZID and greater than placebo) were peripheral edema (7% vs 2%),nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions: Coadministration with strong CYP3A4 inhibitors(e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID doseto 10 mg taken orally as one tablet once daily. Coadministration withstrong CYP3A4 inducers may reduce NUPLAZID exposure. Monitor patientsfor reduced efficacy and an increase in NUPLAZID dosage may be needed.

Pediatric Use: Safety and efficacy have not been established inpediatric patients.

Dosage and Administration: Recommended dose: 34 mg taken orallyonce daily, without titration.

Indication: NUPLAZID is an atypical antipsychotic indicated forthe treatment of hallucinations and delusions associated withParkinson’s disease psychosis.

You are encouraged to report negative side effects of prescription drugsto the FDA. Visit www.fda.gov/medwatch,or call 1-800-FDA-1088. You can also call ACADIA Pharmaceuticals Inc. at1-844-4ACADIA (1-844-422-2342).

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please see the full Prescribing Information including Boxed WARNINGfor NUPLAZID at https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.

Source: ACADIA Pharmaceuticals Inc.

Investor Contact:

ACADIA Pharmaceuticals Inc.
MarkJohnson, CFA
(858) 261-2771
ir@acadia-pharm.com

Media Contact:

ACADIA Pharmaceuticals Inc.
MaurissaMessier
(858) 768-6068
media@acadia-pharm.com